A detailed history of China Universal Asset Management Co., Ltd. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 7,217 shares of KROS stock, worth $435,545. This represents 0.05% of its overall portfolio holdings.

Number of Shares
7,217
Previous 4,239 70.25%
Holding current value
$435,545
Previous $193,000 117.1%
% of portfolio
0.05%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$41.68 - $58.07 $124,123 - $172,932
2,978 Added 70.25%
7,217 $419,000
Q2 2024

Jul 19, 2024

SELL
$44.58 - $66.89 $119,340 - $179,064
-2,677 Reduced 38.71%
4,239 $193,000
Q1 2024

Apr 29, 2024

BUY
$41.26 - $70.48 $142,594 - $243,578
3,456 Added 99.88%
6,916 $458,000
Q4 2023

May 21, 2024

SELL
$27.12 - $41.05 $93,726 - $141,868
-3,456 Reduced 49.97%
3,460 $137,000
Q4 2023

Jan 23, 2024

BUY
$27.12 - $41.05 $73,278 - $110,917
2,702 Added 356.46%
3,460 $138,000
Q3 2023

May 21, 2024

BUY
$31.57 - $43.02 $11,680 - $15,917
370 Added 95.36%
758 $24,000
Q3 2023

Oct 30, 2023

BUY
$31.57 - $43.02 $11,680 - $15,917
370 Added 95.36%
758 $24,000
Q2 2023

May 21, 2024

BUY
$37.26 - $51.01 $558 - $765
15 Added 4.02%
388 $15,000
Q2 2023

Jul 27, 2023

BUY
$37.26 - $51.01 $558 - $765
15 Added 4.02%
388 $16,000
Q1 2023

May 21, 2024

BUY
$41.44 - $59.32 $3,853 - $5,516
93 Added 33.21%
373 $15,000
Q1 2023

Apr 27, 2023

BUY
$41.44 - $59.32 $3,853 - $5,516
93 Added 33.21%
373 $16,000
Q4 2022

May 21, 2024

SELL
$39.45 - $51.77 $261,790 - $343,545
-6,636 Reduced 95.95%
280 $13,000
Q4 2022

Jan 31, 2023

BUY
$39.45 - $51.77 $1,538 - $2,019
39 Added 16.18%
280 $13,000
Q3 2022

Oct 21, 2022

BUY
$27.8 - $40.12 $6,699 - $9,668
241 New
241 $9,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.55B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.